<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840123</url>
  </required_header>
  <id_info>
    <org_study_id>FSJD-DIPG-DC</org_study_id>
    <nct_id>NCT02840123</nct_id>
  </id_info>
  <brief_title>Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines</brief_title>
  <official_title>Phase Ib Clinical Trial on the Safety of Immunotherapy With Autologous Dendritic Cells Primed With Lysate Allogeneic Tumor Lines in Patients With Diffuse Intrinsic Pontine Glioma (DIPG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Sant Joan de Déu</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to asses safety of diffuse intrinsic pontine glioma (DIPG)
      treatment with autologous dendritic cells pulsed with lysated allegenic tumor lines

      Evaluate the nonspecific immune response generated in peripheral blood and Cerebral Spinal
      Fluid (CSF) by proposed treatment Evaluate the specific antitumor immunity response generated
      in peripheral blood and CSF Assess overall survival and progression free survival Correlate
      the neuroradiological changes with the clinical course and immune response generated in
      peripheral blood and CSF Quality of life evaluation
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serious adverse events per patient (after treatment administration</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival Progression free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first Serious Adverse Event (SAE)(after treatment)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diffuse Intrinsic Pontine Glioma</condition>
  <arm_group>
    <arm_group_label>Autologous dendritic cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous dendritic cells</intervention_name>
    <arm_group_label>Autologous dendritic cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed DIPG Patients without progressive disease

          -  Aged between 3 and 18 yo Lansky scale &gt;50 (Karnofsky for patients aged more than 16
             yr)

          -  Life expectancy &gt; 8 weeks

          -  Preserved bone marrow function Normal hepatic and renal function

        Exclusion Criteria:

          -  Impossibility to perform aphaeresis

          -  Patient participation of other experimental study within the last 3 months

          -  Patient under antitumor treatment in the last 4 weeks

          -  Co-morbidity that does not allow the study treatment

          -  Patients requiring &gt; 2mg/day of dexamethasone treatment Corticoid-dependent patients

          -  Patients under uncontrolled infection

          -  Positive serologies of HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

